SITE002-0187

SITE002 (USA) › SITE002-0187

SITE002-0187

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2026-04-16

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-03-12 (study day 139); relationship: NOT RELATED

moderate assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-10 (study day 47); relationship: not assessed

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-04 (study day 41); relationship: NOT RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.